DeepSeq.AI Secures Investment from Zaka VC to Advance AI-Driven Protein Drug Discovery Platform
核心洞察
DeepSeq.AI (搜索) announced an investment from Zaka VC (搜索), alongside funding from Illumina Ventures (搜索) and biotech family offices, to scale its AI-based protein drug (搜索) discovery platform.
The company's proprietary LLM-based technology generates and analyzes large experimental datasets for protein drug (搜索) discovery, including large-scale protein-protein interaction (搜索) data.
DeepSeq's platform is already commercially available and used by major pharmaceutical companies, with validation through DARPA (搜索)-funded initiatives.
DeepSeq.AI (搜索), a privately held biotech company focused on transforming AI-based protein drug (搜索) discovery using hyperscaled data, has secured an investment from Zaka VC (搜索), a prominent Czech-based venture capital firm that has become one of the most active early-stage investors in Europe. The investment, announced on January 7, 2026, comes alongside funding from Illumina Ventures (搜索) and leading biotech-related family offices.
AI-Powered Platform for Protein Drug Discovery
DeepSeq's proprietary large language model (LLM)-based technology can generate and analyze huge experimental datasets for protein (biologics) drug discovery, including large-scale protein-protein interaction (搜索) (PPI) data. This capability allows the company's AI algorithms to discover better drug candidates more efficiently than traditional methods.
"Our large-scale PPI and other data sets, validated through a DARPA (搜索)-funded initiative, will allow our AI algorithms to efficiently discover better protein drug (搜索) candidates," said DeepSeq co-founder and CEO Andrew Chang, Ph.D.
Strategic Investment and Market Validation
The funding will be used to scale DeepSeq's datasets and development teams to meet the demand for future collaborations and partnerships related to protein drug (搜索) discovery. Jan Kasper, Co-Founder and Managing Partner at Zaka VC (搜索), expressed confidence in the company's approach and potential.
"The team brings a strong balance of scientific and commercial expertise, has built a unique data foundation with a compelling moat, and has already demonstrated promising early traction," Kasper said. "Their clear, disciplined thinking around building a scalable protein drug (搜索) discovery platform gives us strong conviction in their long-term potential."
Commercial Traction and Recognition
DeepSeq's commercially available platform is already being used by many big pharma customers, demonstrating real-world validation of its technology. The company has received backing from leading accelerators including Merck Digital Sciences Studio (搜索) (DSS), Stanford StartX (搜索), and Berkeley SkyDeck (搜索), and has been awarded grants from DARPA (搜索) and the National Science Foundation.
The company's achievements have been recognized through several awards, including the 2025 Astellas Future Innovators award and the 2024 MBC Biolabs/ONO "Golden Ticket" award.
Investor Perspective
Chang emphasized the significance of the investment from prominent investors in validating DeepSeq's approach. "As an active investor in the biotech community, ZAKA VC (搜索)'s participation in our funding round, together with other prominent investors like Illumina Ventures (搜索), shows the tremendous promise and value of DeepSeq's approach," he said.
Zaka VC (搜索), which originally formed as a family office in 2019 and has operated as a VC fund since 2024, focuses on investments in biotech, healthcare, and industrial tech verticals. The firm has established an office in San Francisco, California to oversee its activities in North America, bridging its European and North American investment activities.